Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Axitinib | FIMM | pan-cancer | AAC | 0.056 | 0.7 |
mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | -0.01 | 0.7 |
mRNA | ML312 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.7 |
mRNA | EX-527 | GDSC1000 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.01 | 0.7 |
mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.051 | 0.7 |
mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | -0.024 | 0.7 |
mRNA | WH-4-023 | GDSC1000 | pan-cancer | AAC | -0.018 | 0.7 |